Sign in

BLGO on OTC

BIOLARGO, INC.

BIOLARGO, INC. is an American chemicals and allied products company based in Westminster.2 Its shares trade on OTC under the symbol BLGO.2

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with CitroTech Inc., GULF RESOURCES, INC. or ASCENT INDUSTRIES CO., or pick any stock.

  • TickerBLGO on OTC2
  • IndustryChemicals & Allied Products2
  • HeadquartersWestminster, United States2
  • Incorporated inDE3
  • Business address14921 Chestnut St., Westminster, Ca 926833
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI5493007RC0EO4XEQU4432
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O AGENTS AND CORPORATIONS, INC., 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 22743032

See how the biggest companies compare on our leaderboards

You can identify these and other forward-looking statements by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “will,” “would” and similar expressions, or the negative of such terms, although not all forward-looking statements contain these identifying words. Forward-looking statements also include the assumptions underlying or relating to any of the foregoing statements.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

43.9%Gross margin5
-191.3%Operating margin5
-195.6%Net margin5
-56.3%Revenue growth, 20255
-375.8%Return on equity5
0.51×Debt to equity5

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Product brought in 74% of the revenue BIOLARGO, INC. broke down this way in fiscal 2025.

  1. Product$5.8M574%down 66% from 2024
  2. Service$2.0M526%up 96% from 2024
Products and services by year
Products and services20242025
Product$16.8M$5.8M
Service$1.0M$2.0M

Business segments

Odor-No-More brought in 69% of the revenue BIOLARGO, INC. broke down this way in fiscal 2025.

  1. Odor-No-More$5.9M569%down 62% from 2024
  2. BioLargo Engineering, Science & Technologies, LLC$2.5M530%down 20% from 2024
  3. BioLargo Canada$86.0K51%up 19% from 2024
Business segments by year
Business segments20242025
Odor-No-More$15.6M$5.9M
BioLargo Engineering, Science & Technologies, LLC$3.2M$2.5M
BioLargo Canada$72.0K$86.0K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue23¢$4.4M
  • Research and development14¢$2.6M
  • Selling, general and admin63¢$11.8M

Out of $7.8M in revenue.5 The company lost money this year.

Financial statements

Revenue67895$7.8M in 2025+317% since 2019
0$5.0M$10.0M$15.0M$20.0M2019: $1.9M$1.9M20192020: $2.4M$2.4M2020+31%2021: $2.5M$2.5M2021+4%2022: $5.9M$5.9M2022+132%2023: $12.2M$12.2M2023+108%2024: $17.8M$17.8M2024+45%2025: $7.8M$7.8M2025−56%
Gross profit6789105$3.4M in 2025+272% since 2019
0$2.0M$4.0M$6.0M$8.0M2019: $916.0K$916.0K20192020: $1.2M$1.2M2020+34%2021: $1.1M$1.1M2021−10%2022: $2.9M$2.9M2022+159%2023: $6.2M$6.2M2023+115%2024: $7.9M$7.9M2024+28%2025: $3.4M$3.4M2025−57%
Operating income6789105-$14.9M in 2025+122% since 2019
-$15.0M-$10.0M-$5.0M02019: -$6.7M-$6.7M20192020: -$7.6M-$7.6M2020+13%2021: -$6.8M-$6.8M2021−11%2022: -$5.4M-$5.4M2022−20%2023: -$4.6M-$4.6M2023−15%2024: -$4.3M-$4.3M2024−5%2025: -$14.9M-$14.9M2025+243%
Net income6789105-$15.2M in 2025+33% since 2019
-$20.0M-$15.0M-$10.0M-$5.0M02019: -$11.4M-$11.4M20192020: -$9.7M-$9.7M2020−15%2021: -$6.9M-$6.9M2021−29%2022: -$5.1M-$5.1M2022−26%2023: -$4.6M-$4.6M2023−9%2024: -$4.3M-$4.3M2024−6%2025: -$15.2M-$15.2M2025+249%

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-12-312024-12-31
Revenue from Contract with Customer, Including Assessed Tax$7.8M$17.8M
Cost of Goods and Services Sold-$4.4M-$9.9M
Gross profit$3.4M$7.9M
Selling, general and administrative expenses$11.8M$9.3M
Research and development$2.6M$2.9M
Impairment expense$14.0K
Credit Loss Expense$3.9M$0
Total operating expenses$18.3M$12.2M
Operating loss-$14.9M-$4.3M
PPP forgiveness$0$97.0K
Finance fee$0-$106.0K
Grant income$6.0K$26.0K
Interest income$200.0K$38.0K
Interest expense-$540.0K-$71.0K
Total other expense-$334.0K-$16.0K
Net loss attributable to noncontrolling interest-$3.4M-$1.9M
Net loss attributable to common stockholders-$11.8M-$2.4M
Loss per share attributable to stockholders basic and diluted (in dollars per share)-$0.04-$0.01
Weighted average number of common shares outstanding: (in shares)307.0M shares298.1M shares
Net loss-$15.2M-$4.3M
Foreign currency translation adjustment-$24.0K$94.0K
Comprehensive loss-$15.2M-$4.3M
Comprehensive loss attributable to noncontrolling interest-$3.4M-$1.9M
Comprehensive loss attributable to stockholders-$11.8M-$2.3M

Compare BIOLARGO, INC. with another company

What it owns

What BIOLARGO, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$2.2M5 Dec 31, 2025$2.2M5 Dec 31, 2024+2.1%
Accumulated depreciation$607.0K5 Dec 31, 2025$462.0K5 Dec 31, 2024+31.4%
Property and equipment, net$1.6M5 Dec 31, 2025$1.7M5 Dec 31, 2024−5.7%
Finance-lease assets$338.0K5 Dec 31, 2025$451.0K5 Dec 31, 2024−25.1%
Operating-lease assets (leased space)$1.0M5 Dec 31, 2025$992.0K5 Dec 31, 2024+3.6%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$3.9M5 Dec 31, 2025$3.5M5 Dec 31, 2024+9.4%
Stakes in other companies (equity method)$05 Dec 31, 2025$14.0K5 Dec 31, 2024−100.0%

Inventory

ItemLatestA year beforeChange
Inventory, total$310.0K5 Dec 31, 2025$310.0K5 Jan 1, 20250%
Raw materials$125.0K5 Jan 1, 2025$79.0K10 Dec 31, 2023+58.2%
Finished goods$185.0K5 Jan 1, 2025$74.0K10 Dec 31, 2023+150.0%

Properties, in its own words

Our company owns no real property. We currently lease approximately 9,000 square feet of office and industrial space at 14921 Chestnut Street, Westminster, California. In addition to serving as our principal offices, it is also a manufacturing facility where we manufacture our products, including our CupriDyne Clean Industrial Odor control product, and the home of our subsidiary ONM Environmental.

We also lease approximately 22,000 square feet of office, warehouse, lab and manufacturing space at 105 Fordham Road, Oak Ridge, Tennessee, for our professional engineering division, BioLargo Engineering, Science & Technologies, LLC, and our battery company, BioLargo Energy Technologies, Inc. Our subsidiary Clyra Medical leases approximately 450 square feet of office space at 3802 Spectrum Blvd, Tampa Florida and 2,800 of warehouse/flex space at 10770 N. 46th Stret, Unit C-300, Tampa Florida. Our Canadian subsidiary BioLargo Canada leases approximately 1,500 square feet of office and lab space from the University of Alberta in Edmonton, Canada.

The rest of Item 2

Our telephone number is (888) 400-2863.

Item 2 of the 10-K filed Mar 4, 2026.4

Leadership

Who has led BIOLARGO, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Dennis P. Calvert2007–2015

Chair

  1. Dennis P. Calvert2010–2011

President

  1. Dennis P. Calvert2007–now

Chief financial officer

  1. Charles K. Dargan2008–now
2010201520202025
Board members and other officers (13)

Former names

  • NUWAY MEDICAL INCFeb 27, 2003 to Apr 3, 20073
  • NUWAY ENERGY INCOct 19, 2001 to Feb 5, 20033
  • LATIN AMERICAN CASINOS INCAug 20, 1996 to Feb 15, 20013

Timeline

  1. Sep 14, 20268-K Regulation FD disclosure28
  2. Sep 11, 20268-K Regulation FD disclosure29
  3. May 6, 20268-K Regulation FD disclosure30
  4. May 4, 20268-K Regulation FD disclosure31
  5. Mar 25, 20268-K Entered a material agreement; Unregistered sale of shares32
  6. Mar 5, 20268-K Regulation FD disclosure33
  7. Nov 18, 20258-K Other events34
  8. Nov 14, 20258-K Regulation FD disclosure35
  9. Oct 20, 20258-K Regulation FD disclosure36
  10. Sep 25, 20258-K Ended a material agreement; Impairment; Regulation FD disclosure37
  11. Aug 15, 20258-K Regulation FD disclosure38
  12. Jul 23, 20258-K Regulation FD disclosure39
  13. Mar 19, 2007New chief executive Dennis P. Calvert becomes CEO13
  14. Sep 19, 1991Founded BIOLARGO, INC. is founded2

Filings

254 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 44 major events, 124 insider forms, 2 private raises, 63 other. The latest 20:

  1. Oct 2, 20264 EDGAR
  2. Oct 2, 20264 EDGAR
  3. Oct 2, 20264 EDGAR
  4. Oct 2, 20264 EDGAR
  5. Oct 2, 20264 EDGAR
  6. Oct 2, 20264 EDGAR
  7. Sep 14, 20268-K/A EDGAR
  8. Sep 11, 20268-K EDGAR
  9. Aug 14, 202610-Q EDGAR
  10. Jul 7, 20264 EDGAR
  11. Jul 2, 20264 EDGAR
  12. Jul 2, 20264 EDGAR
  13. Jul 2, 20264 EDGAR
  14. Jul 2, 20264 EDGAR
  15. Jul 2, 20264 EDGAR
  16. Jun 24, 20264 EDGAR
  17. May 15, 202610-Q EDGAR
  18. May 6, 20268-K EDGAR
  19. May 4, 20268-K EDGAR
  20. Apr 30, 202610-K/A EDGAR

The 254 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2024ChairmanChief Executive Officer and President$288.6K$318.0K40
2024Chief Science Officer$288.6K$301.2K40
2024Corporate Secretary; President ONM EnvironmentalInc.$193.8K$261.5K40
2024Chief Financial Officer$233.8K40
2023ChairmanChief Executive Officer and President$288.6K$316.6K40
2023Chief Science Officer$288.6K$301.2K40
2023Corporate Secretary; President ONM EnvironmentalInc.$199.3K$258.7K40
2023Chief Financial Officer$140.8K$140.8K40

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$1.5M 2022–2023
Money received by yearMoney received by year, 2022–2023: $1.5M in all. Private raises (Form D) $1.5M.$0$250K$500K$750K$1M2022 · Private raises (Form D): $726.0K20222023 · Private raises (Form D): $815.0K2023
Figures by year
YearPrivate raises (Form D)Total
2023$815.0K$815.0K
2022$726.0K$726.0K

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Nov 17, 2023Raised $815,000 in a private offering of equity41 Form D: 17 investors so far Form D
  2. Apr 18, 2022Raised $726,000 in a private offering of equity42 Form D: $5 million offered in all Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
First American Trust, Fsb117,838$13.4K0.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How BIOLARGO, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARBIOLARGO, INC.1
  • CIK0000880242
  • Employer ID (EIN)65-01591154
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company4
  • Incorporated inDelaware4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2800 Chemicals & Allied Products1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address14921 Chestnut St., Westminster, CA 926831
  • Phone888 400-28631
  • Shares outstanding328,731,362 as of Aug 12, 202612
  • Public float$63.1M as of Jun 30, 20254
  • AuditorHACKER JOHNSON & SMITH PA, Tampa, Florida PCAOB ID 400; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceAug 20, 19961
  • Filings1,160 in all: 4 (484), 8-K (168), 10-Q (56), 10QSB (35), 424B4 (31), EFFECT (31), UPLOAD (26), CORRESP (24)1
    All 48 form types

    DEF 14A (23), POS AM (23), D (22), 4/A (20), 10-K (19), NT 10-Q (17), 3 (15), 5 (15), NT 10-K (14), 10QSB/A (13), 10KSB (11), PRE 14A (11), S-1 (11), S-1/A (10), DEF 14C (7), REGDEX (7), D/A (6), S-8 (6), 10-Q/A (5), PRER14A (5), SC 13G (5), 10KSB/A (4), 8-K/A (4), SC 13D (4), 10-K/A (3), DEL AM (3), POS EX (3), SC 13D/A (3), DEFA14A (2), NTN 10Q (2), PRE 14C (2), RW (2), 3/A (1), ARS (1), DEFA14C (1), NT 10-Q/A (1), NTN 10K (1), S-3 (1), SC 13G/A (1), SEC ACTION (1)

  • Latest filingsAnnual report (10-K) Mar 4, 2026
    Quarterly report (10-Q) Aug 14, 2026
    Proxy statement (DEF 14A) Apr 25, 2025
    Latest 8-K (8-K) Sep 11, 2026

Securities registered for trading

ClassSymbolExchange
Common StockBLGO

From the cover page of the 10-K filed Mar 4, 2026 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks BIOLARGO, INC. names in Item 1A of its 10-K filed Mar 4, 2026: 39 risks under these headings, as written.4

  • Risks relating to our Financial Condition
  • We have incurred net losses on an annual basis since our inception and may continue to experience losses and negative cash flow in the future.
  • Our cash requirements are significant. We will continue to require additional financing to sustain our operations and without it we may not be able to continue operations.
  • Our ability to access capital markets could be limited.
  • We expect to incur future losses and may not be able to achieve profitability.
  • Some of our revenues are dependent on the marketing efforts of third parties.
  • We do not have contracts with customers that require the purchase of a minimum amount of our products.
  • Supply Chain Challenges
  • We rely on a small number of key supply ingredients in order to manufacture our odor control products, including CupriDyne Clean and our private-label products.
  • If any party to which we have outsourced certain functions fails to perform its obligations under agreements with us, the commercialization of our technology could be delayed or curtailed.
  • If our technology or products incorporating our technology do not gain market acceptance, it is unlikely that we will become profitable.
  • If we are not able to manage our anticipated growth effectively, we may not become profitable.
The other 29 risks
  • Some of the products incorporating our technology will require regulatory approval.
  • Our internal controls are not effective.
  • If we lose our key personnel or are unable to attract and retain additional personnel, we may be unable to achieve profitability.
  • Nondisclosure agreements with employees and others may not adequately prevent disclosure of trade secrets and other proprietary information.
  • We may become subject to product liability claims.
  • Litigation or the actions of regulatory authorities may harm our business or otherwise distract our management.
  • If we suffer negative publicity concerning the safety or efficacy of our products, our sales may be harmed.
  • Our revenues and operating results are likely to continue to fluctuate from quarter to quarter.
  • The licensing of our technology or the manufacture, use or sale of products incorporating our technology may infringe on the patent rights of others, and we may be forced to litigate if an intellectual property dispute arises.
  • Our patents are expensive to maintain, our patent applications are expensive to prosecute, and thus we are unable to file for patent protection in many countries.
  • We are subject to risks related to future business outside of the United States.
  • The volatility of certain raw material costs may adversely affect operations and competitive price advantages for products that incorporate our technology.
  • Certain of our product sales historically have been highly impacted by fluctuations in seasons and weather.
  • There may be battery technologies that we are not aware of, and some of them may be subject to patent applications.
  • We expect to face strong competition for our products from a growing list of established and new competitors.
  • There may not be a market for our liquid sodium battery.
  • Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.
  • General Risks
  • Increased information technology security threats and more sophisticated computer crime pose a risk to us and our subsidiaries, vendors, systems, networks, products and services.
  • Economic uncertainties, recession, and domestic or world events and policies may adversely affect our business and operations.
  • Risks Relating to our Common Stock
  • The sale or issuance of our common stock to any equity line provider causes dilution, and the sale of the shares of common stock acquired by any such provider, or the perception that such sales may occur, could cause the price of our common stock to fall.
  • Our common stock is thinly traded and largely illiquid.
  • The market price of our stock is subject to volatility.
  • You may have difficulty selling our stock because it is deemed a “penny stock” and not quoted on a national exchange.
  • Because our shares are deemed a “penny stock,” rules enacted by FINRA make it difficult to sell previously restricted stock.
  • Because we will not pay dividends in the foreseeable future, stockholders will only benefit from owning common stock if it appreciates.
  • We regularly issue stock, or stock options, instead of cash, to pay some of our operating expenses. These issuances are dilutive to our existing stockholders.
  • Our stockholders face further potential dilution in any new financing.
  • Our stockholders face further potential adverse effects from the terms of any preferred stock that may be issued in the future.
  • Risks Related to Privacy, Cybersecurity, and Our Technology
  • Our business involves the use, transmission and storage of confidential information, and the failure to properly safeguard such information could result in significant reputational harm.

Legal proceedings

ONM Environmental, Inc., is the defendant in a lawsuit filed by Pooph Inc. in the Orange County, California Superior Court on September 11, 2025. The lawsuit alleges three causes of action, for Breach of Contract, Breach of Implied Covenant of Good Faith and Fair Dealing, and Declaratory judgment, and seeks an unspecified amount of damages, allegedly arising from ONM’s manufacture of pet odor-control products sold by Pooph Inc.

BioLargo, Inc., BioLargo Life Technologies, Inc., and ONM Environmental, Inc., filed a lawsuit against Pooph, Inc., and Ikigai Marketing Works, LLC, in the United States District Court, Central District of California, on November 11, 2025, for patent infringement, false advertising, breach of contract, false promise, unfair and fraudulent business practices and constructive fraud, seeking to recover, amongst other damages, the defendants’ failure to pay for product purchases and license royalties in the aggregate amount of $3,821,401.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
    SEC EDGAROther events
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42